KRAS and neoplasm: Indeed, alterations in KEAP1 and/or STK11, which are especially frequent in KRAS-mutated tumours, promote an immunosuppressive tumour microenvironment, enriched in suppressive myeloid cells and depleted in CD8+ cytotoxic T cells, but with relative sparing of CD4+ effector T cells.